Physician profile
Rodney E Snow
NPI 1770798506
$180,651.44
in general payments reported to CMS, 2019-2025
34 companies · $91K in 2025
The $91K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,695 · 2021: $31K · 2022: $12K · 2023: $6,663 · 2024: $7,378 · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Food and Beverage: $11K · Travel and Lodging: $5,195 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,147.00 |
| Food and Beverage | $10,911.18 |
| Travel and Lodging | $5,195.24 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $87,718.70 | 2023-2025 | Yorvipath |
| Mannkind Corporation | $34,460.26 | 2019-2025 | Afrezza |
| Medtronic, INC. | $21,481.63 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Shire North American Group INC | $15,045.75 | 2019 | |
| Insulet Corporation | $7,374.85 | 2019-2025 | Omnipod |
| Zealand Pharma US, INC. | $3,219.17 | 2021-2022 | |
| Novo Nordisk INC | $1,895.75 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $1,783.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,559.15 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Cequr Corporation | $944.35 | 2023-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.20 | 2020-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $538.58 | 2023-2025 | Gvoke Hypopen |
| Companion Medical, INC. | $500.00 | 2020 | |
| Amgen INC. | $486.74 | 2020-2025 | Repatha, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $438.21 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $396.32 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $383.24 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $274.39 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $214.85 | 2021-2025 | Unithroid |
| Corcept Therapeutics | $197.06 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $193.22 | 2019-2020 | |
| Dexcom, INC. | $135.13 | 2021-2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $97.26 | 2023-2025 | Licart, Tirosint, Tirosint |
| Abbvie INC. | $90.06 | 2021-2024 | Ubrelvy |
| Amphastar Pharmaceuticals, INC. | $81.98 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.06 | 2022 | |
| Ascensia Diabetes Care US INC. | $70.47 | 2023 | |
| Bigfoot Biomedical INC | $26.16 | 2023 | Unity Diabetes Management System |
| Kyowa Kirin, INC. | $25.12 | 2023 | Crysvita |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Glaxosmithkline, LLC. | $20.51 | 2025 | Arexvy, Shingrix |
| Halozyme INC | $18.61 | 2023 | |
| Nevro Corp. | $14.75 | 2023 | Senza |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.